课题基金 / 基金详情

HLA IN DISEASE AND TRANSPLANTATION

HLA IN DISEASE AND TRANSPLANTATION
HLA 在疾病和移植中的作用
批准号:
3150689
负责人:
PAUL I TERASAKI
金额:
$11.6万
依托单位国家:
美国
项目类别:
财政年份:
1976
资助国家:
美国
项目状态:
已结题
起止时间:
1976-12-01 至 1986-12-31

项目摘要

项目成果

PAUL I TERASAKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary aim of this project will be continued study of the allograft problem. Studies of factors influencing transplant survival will utilize an extensive data base collected over the past 12 years and analyses will be done using an on-site computer facility. Factors to be examined include HLA-DR histocompatibility matching, possible enhancing antibodies, and the transfusion effect. Efforts will be made to devise means by which enhancing antibodies induced by transfusiuons can be detected. Sera from patients who subsequently reject grafts will be compared to those with successful grafts. Antimmunoglobulin antibodies are the principal antibodies postulated to be enhancing antibodies.
期刊论文(48)
专著(0)
科研奖励(0)
会议论文
ABO incompatibility in cadaver donor kidney allografts.
尸体供体肾同种异体移植物中 ABO 不相容。
DOI: --
发表时间: 1987
期刊: Transplantation proceedings
影响因子: 0.9
作者: [Cook,DJ, Graver,B, Terasaki,PI]
通讯作者: Terasaki,PI
Lymphocytotoxic definition of combined ABH and Lewis antigens and their transfer from sera to lymphocytes.
ABH 和 Lewis 组合抗原的淋巴细胞毒性定义及其从血清到淋巴细胞的转移。
DOI: 10.1016/0198-8859(80)90014-2
发表时间: 1980
期刊: Human immunology
影响因子: 2.7
作者: [Oriol,R, Danilovs,J, Lemieux,R, Terasaki,P, Bernoco,D]
通讯作者: Bernoco,D
Discrimination of T, B, and null lymphocytes by electronic sizing.
通过电子尺寸区分 T、B 和无效淋巴细胞。
DOI: 10.1111/j.1399-0039.1980.tb00195.x
发表时间: 1980
期刊: Tissue antigens
影响因子: --
作者: [El-Awar,N, Terasaki,PI, Perdue,S, Cicciarelli,J, Mickey,MR]
通讯作者: Mickey,MR
Cytotoxicity of anti-Fab antibodies against B lymphocytes in rheumatoid arthritis.
类风湿性关节炎中抗 Fab 抗体针对 B 淋巴细胞的细胞毒性。
DOI: 10.1002/art.1780241007
发表时间: 1981
期刊: Arthritis and rheumatism
影响因子: --
作者: [Nasu,H, Chia,D, Iwaki,Y, Barnett,EV, Terasaki,PI]
通讯作者: Terasaki,PI
44
    PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCER
    PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCER
    MONOCLONAL ANTIBODIES TO TREAT KIDNEY GRAFT REJECTION
    MONOCLONAL ANTIBODIES TO TREAT KIDNEY GRAFT REJECTION
    海外基金